Medical Drugs Equipment Supplied In Switzerland

Optofluidic Technology is the Key to Faster Workflows and Deeper Data. See how opto-electropositioning (OEP) technology moves Cell Biology to light speed. Our technology combines precise cell processing, time-saving workflow automation, and rich, deep profiling. Watch this video animation, to see how Berkeley Lights advanced technology works. Welcome to the ...

To bio-engineer denovoSkin™, a small biopsy of healthy skin is harvested from the patient. The biopsy is processed to isolate epidermal and dermal cells. The cells are expanded in vitro, and thereafter used in combination with a hydrogel to create a dermo-epidermal skin graft. denovoSkin™ is now ready to be transplanted on the patient’s wounds. The safety trials for ...

We introduce a novel ultra-light suction device, NIMBLEeva, overcoming the limits of the existing instruments. The specific working principle enables a lightweight design, preventing interaction between the observer and the suction probe, and by this the measurement outcome significantly ...

Mucopolysaccharidosis type 1 (MPS 1) is a rare lysosomal storage disease that is caused by mutations in IDUA, the gene that encodes the alpha-L-iduronidase (IDUA) enzyme. These mutations cause the misfolding and dysfunction of IDUA, which leads to the toxic buildup of large sugars in the bone, cartilage, cornea, heart and central nervous system (CNS). There is currently no cure for these ...

STALICLA’s precision medicine approach begins with ‘endophenotyping’-identifying the nonbehavioral physical and molecular presentations of NDDs and characterizing subgroups of patients with similar disease signatures. DEPI matches these patient subgroups with an NDD-targeted drug (or drug combination) by integrating and analyzing large omics data sets, including genomics, ...

The Prefilled ApiJect Injector* is a delivery system designed to bring together the benefits of prefilled syringes with the manufacturing efficiency of multi-dose ...

An in vitro PDX model with in vivo-like heterogeneity. 3D InSight™ Tumor Microtissues from Patient-Derived Xenografts (PDX) are custom assay-ready 3D in vitro tumor models engineered to reflect complex tumor biology without the use of artificial matrices. Ideal for early stage cancer drug efficacy testing and screening appliciations, these advanced cancer models help bridge the gap between ...

Available in 125 or 500 mL. Ready-to-use, serum-free, chemically defined. Contains growth factors and Phenol Red. Supplemented by default with antibiotics ...

A class selective MIP phase for the multi-residue extraction of beta-agonists in urine, tissues, and other biological fluids. SupelMIP - Beta-agonists was developed for the selective extaction of a broad range o beta-agonists such as brombuterol, clenbuterol, formoterol, isoxuprine, mapenterol, ractopamine, ritrodine, salbutamol, salmeterol, terbutaline, tulobuterol, zilpaterol and others. The ...

A class selective MIP phase for the multi-residue extraction of beta-agonists in urine, tissues, and other biological fluids. SupelMIP - Beta-agonists was developed for the selective extaction of a broad range o beta-agonists such as brombuterol, clenbuterol, formoterol, isoxuprine, mapenterol, ractopamine, ritrodine, salbutamol, salmeterol, terbutaline, tulobuterol, zilpaterol and others. The ...

A class selective MIP phase for the multi-residue extraction of beta-blockers in water and biological fluids. SupelMIP - Beta-blockers was developed for the selective extaction of a broad range of beta-blockers such as altenolol, betaxolol, carazolol,metroprolol, pindolol, propanolol, sotalol and timolol, and others. The SupelMIP cartridge offers excellent reproducibility for surveillance of ...

The CADD-Solis Infusion System offers a modern portable design with wireless connectivity and versatility for pain management. Supported therapies ...

Maintain a needlefree closed system to help minimize exposure to hazardous drugs and comply with USP. Prohibits the escape of hazardous drug or vapor concentrations, Blocks the transfer of environmental contaminants into the system, Eliminates needlestick injuries while minimizing , hazardous drug exposure. With the ChemoLock needlefree CSTD, it has never been easier to keep yourself safe from ...

The 3D InSight™ Steatosis Model is an advanced human disease model that enables you to screen compounds and investigate disease pathophysiology using a physiologically relevant human liver microtissue that recapitulates the first stage of non-alcoholic fatty liver disease: accumulation of lipids in liver hepatocytes. Available as an assay-ready model delivered to your lab, or for use ...

Test efficacy of anti-NASH drugs in an advanced 3D human liver disease model. The InSphero 3D InSight™ Human Liver NASH Model consists of an advanced microtissue co-culture of healthy primary human liver cells combined with specially formulated media and cocktails that induce the progression of NAFLD and NASH from steatosis to liver inflammation and fibrosis. Ideal for investigating ...

The Quantum Blue® Adalimumab assay measures from 1.3 to 35 µg/ml. The target concentrations for the optimal therapeutic window lies well within the linear range of the test. Quantum Blue® Adalimumab provides a quantitative result within 15 minutes of incubation time. This offers the possibility to health care providers to act immediately while following up the patient’s ...

The Quantum Blue® Infliximab assay measures from 0.4 to 20 µg/mL. The target concentrations for trough level interpretation lies well within the linear range of the test. Quantum Blue® Infliximab provides a quantitative result within 15 minutes of incubation time. This offers the possibility to health care providers to act immediately before infusion of the next infliximab dose. ...

iLink is the first and only FDA-approved corneal cross-linking procedure that slows or halts the progression of keratoconus and helps preserve vision. Watch this video for unique patient and doctor perspectives about progressive keratoconus and learn how the condition is treated with iLink™ corneal cross-linking. ...

As a general contractor and system integrator we design, develop and install high-quality turnkey process plants. Our customers include medium-sized and large enterprises in the food and pharmaceutical and many other industries. JAG has all the in-house expertise and resources needed to design and build an automated production ...

Actemra/RoActemra is approved in 116 countries for the treatment of rheumatoid arthritis (RA). It is also approved for the treatment of paediatric juvenile idiopathic arthritis (pJIA), systemic juvenile idiopathic arthritis (sJIA), giant cell arteritis (GCA) and CAR-T cell-induced cytokine release syndrome (CRS). Actemra/RoActemra is available in both subcutaneous (SC) and intravenous (IV) ...